This review discusses the pathophysiology of heart failure and the clinical rationale for using carvedilol to decrease morbidity and mortality.
Answers are grounded in this paper and cite their sources.
Challenges historical beta-blocker contraindication in heart failure; leaves open randomized confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marie Taccetta-Chapnick (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: